BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 11923116)

  • 1. Stimulation of local antibody production: parenteral or mucosal vaccination?
    Bouvet JP; Decroix N; Pamonsinlapatham P
    Trends Immunol; 2002 Apr; 23(4):209-13. PubMed ID: 11923116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modern mucosal vaccines, adjuvants and microbicides.
    Cranage MP; Manoussaka M
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):21-3. PubMed ID: 19622054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights in mucosal vaccine development.
    Pavot V; Rochereau N; Genin C; Verrier B; Paul S
    Vaccine; 2012 Jan; 30(2):142-54. PubMed ID: 22085556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal vaccination.
    Woodland DL
    Viral Immunol; 2013 Apr; 26(2):125. PubMed ID: 23573978
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent progress in mucosal vaccine development: potential and limitations.
    Lycke N
    Nat Rev Immunol; 2012 Jul; 12(8):592-605. PubMed ID: 22828912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal vaccines: Strategies and challenges.
    Li M; Wang Y; Sun Y; Cui H; Zhu SJ; Qiu HJ
    Immunol Lett; 2020 Jan; 217():116-125. PubMed ID: 31669546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.
    Srivastava A; Gowda DV; Madhunapantula SV; Shinde CG; Iyer M
    APMIS; 2015 Apr; 123(4):275-88. PubMed ID: 25630573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of new candidates as mucosal vaccine adjuvant in TNF family cytokines.
    Kayamuro H; Yoshioka Y; Abe Y; Katayama K; Arita S; Nomura T; Yoshikawa T; Itoh N; Kamada H; Tsunoda S; Tsutsumi Y
    Adv Exp Med Biol; 2011; 691():299-304. PubMed ID: 21153334
    [No Abstract]   [Full Text] [Related]  

  • 9. Mucosal vaccination and therapy with genetically modified lactic acid bacteria.
    Wells J
    Annu Rev Food Sci Technol; 2011; 2():423-45. PubMed ID: 22129390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery.
    Wang SH; Thompson AL; Hickey AJ; Staats HF
    Curr Top Microbiol Immunol; 2012; 354():121-56. PubMed ID: 21822816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal responses to parenteral and mucosal vaccines.
    Kaul D; Ogra PL
    Dev Biol Stand; 1998; 95():141-6. PubMed ID: 9855424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in vaccine adjuvants for systemic and mucosal administration.
    O'Hagan DT
    J Pharm Pharmacol; 1998 Jan; 50(1):1-10. PubMed ID: 9504429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines against mucosal infections.
    Holmgren J; Svennerholm AM
    Curr Opin Immunol; 2012 Jun; 24(3):343-53. PubMed ID: 22580196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New routes of administration: epidermal, transcutaneous mucosal ways of vaccination].
    Denis F; Alain S; Ploy MC
    Med Sci (Paris); 2007 Apr; 23(4):379-85. PubMed ID: 17433227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines.
    Jin Z; Gao S; Cui X; Sun D; Zhao K
    Int J Pharm; 2019 Dec; 572():118731. PubMed ID: 31669213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal and systemic responses of immunogenic vaccines candidates against enteric Escherichia coli infections in ruminants: A review.
    Lawan A; Jesse FFA; Idris UH; Odhah MN; Arsalan M; Muhammad NA; Bhutto KR; Peter ID; Abraham GA; Wahid AH; Mohd-Azmi ML; Zamri-Saad M
    Microb Pathog; 2018 Apr; 117():175-183. PubMed ID: 29471137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent developments in nanocarrier-aided mucosal vaccination.
    Kammona O; Bourganis V; Karamanidou T; Kiparissides C
    Nanomedicine (Lond); 2017 May; 12(9):1057-1074. PubMed ID: 28440707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells.
    Stary G; Olive A; Radovic-Moreno AF; Gondek D; Alvarez D; Basto PA; Perro M; Vrbanac VD; Tager AM; Shi J; Yethon JA; Farokhzad OC; Langer R; Starnbach MN; von Andrian UH
    Science; 2015 Jun; 348(6241):aaa8205. PubMed ID: 26089520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mucosal immunity and vaccine development].
    Anjuère F; Czerkinsky C
    Med Sci (Paris); 2007 Apr; 23(4):371-8. PubMed ID: 17433226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel vaccine development strategies for inducing mucosal immunity.
    Fujkuyama Y; Tokuhara D; Kataoka K; Gilbert RS; McGhee JR; Yuki Y; Kiyono H; Fujihashi K
    Expert Rev Vaccines; 2012 Mar; 11(3):367-79. PubMed ID: 22380827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.